Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today highlights ...
Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...
The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and ...
Non-toxic stem cell treatment restores insulin-producing cells and reverses type 1 diabetes in mice, offering hope for future therapies.
NEW YORK, USA, August 21, 2023/EINPresswire.com/ -- Altucell Therapeutics is making monumental advancements in the realm of diabetes care. The company remains at the ...
SAN FRANCISCO--(BUSINESS WIRE)--Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing ...
(NASDAQ: KLTO) has been selected as winner of the Fifth Annual BioTech Breakthrough Award in the "Cell Therapy Innovation of the Year" category for its pioneering work developing transformative gene ...
Scientists at the University of Wisconsin–Madison have uncovered a possible way to protect key cells in the pancreas that are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results